Pharmafile Logo
Pharmafocus logo
Advanced Search

Manufacturing and Production

Showing 15 posts of 5869 posts found.

theresa_may

Theresa May promises £2 billion a year in funding for R&D

November 21, 2016 Manufacturing and Production, Medical Communications Conservative, Theresa May, brexit

The Conservative Party leader has announced a planned raise in funding for research and development for UK business to £2 …
News

Acorda forced to stop development of drug

November 21, 2016 Manufacturing and Production, Research and Development Acorda therapeutics, clinical trial, post-stroke

Acorda Therapeutics announced that they were unable to continue development of the drug, dalfampridine, due to lack of efficacy in …
News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

November 18, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Celgene, Crohn's, Janssen, otezla, top ten

While the world is still reeling from the US presidential election results; it’s business as usual for the pharma industry; …
News
flag_of_japan_

Japan to slash Opdivo costs by 50%

November 17, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Japan, opdivo

Japan’s health ministry has announced it is to slash the price of Bristol-Myers Squibb’s Opdivo by 50% in the country …
News
amgen_hq

Amgen boosted in race to market for migraine drug

November 17, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, Novartis, erenumab, migraine, phase III

Amgen released positive results from their second Phase III trial for experimental migraine drug, known as erenumab, which it is …
News
nice_reception

NICE rules Shire’s Onivyde not cost effective

November 17, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS, NICE, Onivyde, Shire

Shire’s Onivyde has been determined by NICE as not cost effective, in draft guidance, despite adding on average two months …
News
images

NICE approves Roche’s Perjeta for breast cancer

November 16, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NICE, Perjeta, Roche, breast cancer

NICE has announced its approval of Roche’s Perjeta (pertuzumab) as a neoadjuvant treatment of HER2-positive, locally advanced, inflammatory or early-stage …
News

Myelofibrosis market to increase to be worth over $1 billion by 2025

November 16, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EU, US, myelofibrosis

The myelofibrosis market is expected to grow from $545.2 million in 2015 to $1.02 billion by 2025, almost doubling in …
News
shutterstock_292920209

Real world evidence: a reality check for pharma?

November 16, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing real world evidence

Rising demands on the industry has pharma firms calling for a more-effective, fit-for-purpose methodology for generating clinical data. Could the …
Feature
nordic-nanovector-big

New CMO and Executive Management Team member for Nordic Nanovector

November 15, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Nordic Nanovector has recruited a new chief medical officer (CMO) and Executive Management Team member with the appointment of Dr …
Appointment

Novartis reportedly in talks to acquire Amneal in $8 billion deal

November 15, 2016 Manufacturing and Production, Sales and Marketing Amneal pharmaceuticals, Novartis, joe jimenez

Novartis are said to be eyeing a deal for Amneal pharmaceuticals in order to bolster its Sandoz generics business. Bloomsberg …
News
celgene_1_02

Celgene’s Otezla hits primary endpoint in psoriatic arthritis study

November 15, 2016 Manufacturing and Production, Research and Development Celgene, otezla, psoriatic arthritis

Celgene has unveiled new data on its selective inhibitor of phosphodiesterase 4 (PDE4) Otezla (apremilast) which shows that the treatment …
News
abbvie_0

AbbVie investigational hep C drug boasts 97.5% response rate

November 15, 2016 Manufacturing and Production, Medical Communications, Research and Development AbbVie, hepatitis C, pan-genotypic

AbbVie released details on their latest trials for their investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530). In an eight week …
News

Novartis reveals positive three-year efficacy data for psoriatic arthritis drug

November 15, 2016 Manufacturing and Production, Research and Development Cosentyx, Novartis, psoriatic arthritis

Novartis has claimed that its Cosentyx (secukinumab) treatment is now the first approved fully human interleukin-17A (IL-17A) inhibitor to demonstrate …
News
teva_copy

Teva’s white elephant plant in Mexico inoperative

November 14, 2016 Manufacturing and Production Mexico, Rimsa, Teva

The Teva-Rimsa debacle continues to rumble on, with Teva’s plant in Mexico not producing any drugs for market. The plant …
News
The Gateway to Local Adoption Series

Latest content

Campaign highlights low expectations among patients with depression

May 7, 2026

Practical AI toolkit launched to help manufacturers cut through complexity

May 6, 2026

Syngene appoints Maninder Kapoor Puri as CHRO

May 6, 2026

BioPhorum acquires PharmaX Solutions

May 5, 2026

Syngene appoints Abhijit Zutshi as CCO

May 5, 2026